Sequoia raises $200m Israel VC fund

The Sequoia Capital Israel V LP Fund will be an early-stage fund that will focus on investments in information technology.

Sequoia Capital is set to complete raising a new $200 million venture capital fund for Israel investments. Sequoia Capital Israel V LP will be an early-stage fund focusing mainly on information technology start ups. Raising of the funds will be completed in September.

Sequoia Capital, is a veteran venture capital fund based in Silicon Valley currently celebrating its 40th anniversary. Over the years, it has backed some of the biggest names in the technology industry including Apple Inc., Yahoo! Inc., Google Inc., LinkedIn and Cisco Systems.

The new Israeli venture capital fund is one of three new funds being raised by Sequoia. The others will focus on the US and China and the total of the three funds will be $975 million.

The firm has always raised separate funds for Israel and has $580 million in its previous four Israeli funds. The last two Sequoia Israel funds have each been $200 million in size, while its first fund was just $30 million in size, and its second fund was $150 million. Investments have included Provigent, acquired by Broadcom, Attenti Holdings acquired by 3M, Snaptu acquired by Facebook, Storwize acquired by IBM, BitBand acquired by Motorola, and Amobee acquired by SingTel.

Published by Globes [online], Israel business news - www.globes-online.com - on August 23, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Yaron Daniely Replacing Ritalin

Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.

Twitter Facebook Linkedin RSS Newsletters גלובס